Read on Twitter
$NVCR A 
on why I have been buying since late 2016 and think the SP could go to $500.
In 2000 Yoram Palti created a new cancer treatment based on his hypothesis that alternating electric fields when applied at specific freq. can disrupt cancer cell div. and cause cell death.
on why I have been buying since late 2016 and think the SP could go to $500. In 2000 Yoram Palti created a new cancer treatment based on his hypothesis that alternating electric fields when applied at specific freq. can disrupt cancer cell div. and cause cell death.
“Nobody understood what I was doing" Professor Palti said of his early development of Tumor Treating Fields. I still think this somewhat applies today. Many still feel like the tech is like snake oil but $NVCR has said that this works in every cancer cell tested in the lab!
The company has managed to get FDA approval and medicare reimbursement for GBM treatment and FDA aprov. for meso which is very impressive considering this was a new treatment never seen before. Revenue from the GBM and mesothelioma indications has continued to grow at a good clip
What convinced me that this was a long term winner was when the company showed this slide indicating that the higher the intensity and longer time wearing the device produced the longest survival times. #gamechanger
$NVCR management is also very impressive. Listening to Bill Doyle, executive chairman for the past 4+ years has shown that he is one of the best executives I have come across. Take a second to look at his background and listen to the earnings calls. https://www.novocure.com/leadership/william-f-doyle/
In 2020 they had an excellent year despite the pandemic. Getting approval for GBM in China through their partner $ZLAB (another one of my larger holdings) I'll do a seperate thread on this amazing company later. https://www.globenewswire.com/news-release/2020/05/13/2032766/0/en/China-NMPA-Approves-Optune-for-the-Treatment-of-Newly-Diagnosed-and-Recurrent-Glioblastoma.html
Additionally they have a partnership with $MRK Merck to study how TTF and Keytruda in 1st line NSCLC work in combo. Also they secured a 575M convertible note with a 0% interest rate further strengthening their cash position. I don't expect them to raise additional capital.
This is $NVCR 's current pipeline of several late stage assets and PH2 trials. Keep in mind these indications are much more frequent compared to GBM and mesothelioma.
This year there are 5, YES 5! data readouts expected.
The company is also investing in innovation including a smaller device, higher intensity arrays, and software for new indications. These could easily extend survival by 6 months on top of the current results.
Bill Doyle has said $NVCR is preparing for a period of significant growth and innovation and I believe him.
This is not investment advice and I encourage you to do your own research and ask questions. https://www.ted.com/talks/bill_doyle_treating_cancer_with_electric_fields
This is not investment advice and I encourage you to do your own research and ask questions. https://www.ted.com/talks/bill_doyle_treating_cancer_with_electric_fields
